Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Notes Payables (2022 - 2025)

Dexcom (DXCM) has disclosed Notes Payables for 4 consecutive years, with $1.2 billion as the latest value for Q3 2025.

  • On a quarterly basis, Notes Payables changed N/A to $1.2 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $1.2 billion, a N/A change, with the full-year FY2024 number at $1.2 billion, changed N/A from a year prior.
  • Notes Payables was $1.2 billion for Q3 2025 at Dexcom, roughly flat from $1.2 billion in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $1.2 billion in Q3 2025 to a low of $124.2 million in Q3 2023.
  • A 4-year average of $908.3 million and a median of $989.1 million in 2023 define the central range for Notes Payables.